Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03947138
Other study ID # GC3107_P3
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 6, 2019
Est. completion date September 6, 2022

Study information

Verified date October 2022
Source GC Biopharma Corp
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the efficacy and safety of GC3107 in healthy infants


Description:

The study will be conducted in 2 Countries, Korea and Thailand. About 750 subjects will be enrolled to this study. This clinical trial consists of Part 1 to compare the efficacy and safety between the study group and the active control group and Part 2 for the final safety assessment. Subject enrollment for Part 1 and Part 2 will occur at the same time, and subjects who meet the final inclusion/exclusion criteria will be randomized to Part 1 or Part 2 via the IWRS. When the legally acceptable representative of the subject within 4 weeks after birth consents to participate in the clinical study in writing at Visit 1, the protocol-mandated examination and tests will be performed at each visit, and only the subjects who meet the inclusion/exclusion criteria will be assigned randomization numbers and receive a single intradermal injection of the investigational product. However, the informed consent of the subject's legally acceptable representative for participation in the clinical trial may be obtained between 36 weeks of pregnancy of a subject's mother and Visit 1. The investigator will instruct the subject's legally acceptable representative to record any adverse events (AEs) occurring after administration of the investigational product to assess the safety of the subject during the study period. The subjects participating in Part 1 will have the tuberculin skin test at Visit 4 for the efficacy assessment and receive an intradermal injection of 0.1 mL purified protein derivatives (PPD) reagent. Visit 5 will occur within 48 to 72 hours of the PPD reagent injection to check the tuberculin skin test results. Also, Visit 6 will be conducted as an on-site visit to check for any solicited local AEs (abscess, ulcer, scar, and BCG lymphadenitis) and unsolicited AEs occurring until 6 months (168 days) after administration of the investigational product.


Recruitment information / eligibility

Status Completed
Enrollment 750
Est. completion date September 6, 2022
Est. primary completion date June 20, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 4 Weeks
Eligibility Inclusion Criteria: 1. Subject's legally acceptable representatives had this clinical trial information explained to them and understood it, voluntarily decided participation, and provided informed consent 2. Healthy infants aged=4weeks 3. Body weight=2,500g at birth 4. Born after normal gestation(=37weeks) Exclusion Criteria: 1. Had contact with patients with a confirmed diagnosis of active pulmonary tuberculosis 2. Any symptoms or signs of active tuberculosis infection or current treatment of tuberculosis at screening 3. History of confirmed tuberculosis 4. Acute fever with tympanic temperature=38.0 'C within 24 hours prior to administration of the investigational product, or an active infections disease at screening 5. Hypothermia with tympanic temperature<36.0 'C within 24 hours prior to administration of the investigational product 6. Clinically suspected neonatal sepsis 7. Born with severe congenital anomaly that may affect the efficacy or safety result of this clinical trial as judged by the investigator 8. Severe skin disease or burn at the injection site of investigational product 9. The subject's mother had human immunodeficiency virus (HIV)-positive result on prenatal testing

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
GC3107
BCG Vaccine
Intradermal BCG SSI inj.
BCG Vaccine

Locations

Country Name City State
Korea, Republic of The Catholic Universitiy of Korea St. vincent's Hospital Suwon
Korea, Republic of Greencross Yongin

Sponsors (1)

Lead Sponsor Collaborator
Green Cross Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of subjects with maximum diameter of induration = 5mm in the tuberculin skin test Induration diameter measured in the direction perpendicular to the arm. 84 days after administration of the investigational product
Secondary Proportion of subjects with maximum diameter of induration <5mm, = 5mm to <10mm and =10mm in the tuberculin skin test Induration diameter measured in the direction perpendicular to the arm. 84 days after administration of the investigational product
Secondary Proportion of subjects with maximum diameter of erythema = 5mm in the tuberculin skin test Erythema diameter measured in the direction perpendicular to the arm. 84 days after administration of the investigational product
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2